| |
Odds Ratio
|
Confidence Interval
|
P-value
|
|---|
|
Race
|
|
Black
|
Reference
| | |
|
White
|
1.47
|
0.50–4.32
|
p = 0.48
|
|
Hispanic
|
1.34
|
0.43–4.19
|
p = 0.62
|
|
Other
|
0.42
|
0.05–3.74
|
p = 0.43
|
|
Age
|
0.96
|
0.93–1.00
|
p = 0.08
|
|
Gender
|
|
Male
|
Reference
| | |
|
Female
|
0.20
|
0.03–1.33
|
p = 0.10
|
|
Insurance
|
|
Private
|
Reference
| | |
|
Medicare
|
0.48
|
0.13–1.84
|
p = 0.29
|
|
Medicaid
|
0.69
|
0.08–5.77
|
p = 0.74
|
|
Self
|
0.23
|
0.03–1.57
|
p = 0.13
|
|
Income by ZIP code*
|
|
Quartile 1
|
Reference
| | |
|
Quartile 2
|
3.61
|
0.95–13.67
|
p = 0.06
|
|
Quartile 3
|
5.35
|
1.35–21.26
|
p = 0.017
|
|
Quartile 4
|
4.38
|
1.00–19.13
|
p = 0.049
|
|
Risk factors
|
|
HTN
|
6.85
|
2.68–17.52
|
p = 0.0001
|
|
HLD
|
1.07
|
0.41–2.81
|
p = 0.90
|
|
CAD
|
0.15
|
0.01–1.63
|
p = 0.12
|
|
Arrhythmia
|
1.82
|
0.35–9.52
|
p = 0.48
|
|
DM
|
1.78
|
0.67–4.75
|
p = 0.25
|
|
Smoking
|
1.18
|
0.47–2.99
|
p = 0.73
|
|
FH
|
0.79
|
0.29–2.13
|
p = 0.64
|
|
Age > 65
|
4.01
|
0.10–16.17
|
p = 0.051
|
|
Cancer type
|
|
Breast cancer
|
Reference
| | |
|
Other cancer^
|
0.12
|
0.02–0.74
|
p = 0.02
|
|
Cancer stage
|
|
Stage 1
|
Reference
| | |
|
Stage 2
|
0.31
|
0.05–1.83
|
p = 0.20
|
|
Stage 3
|
0.16
|
0.02–1.33
|
p = 0.09
|
|
Stage 4
|
0.23
|
0.03–1.78
|
p = 0.16
|
|
Chemotherapy
|
|
Doxorubicin
|
1.49
|
0.34–6.53
|
p = 0.60
|
|
Herceptin
|
0.70
|
0.12–3.97
|
p = 0.68
|
|
Medications pre-chemotherapy
|
|
BB
|
2.04
|
0.46–9.06
|
p = 0.35
|
|
ACEI/ARB
|
0.16
|
0.04–0.70
|
p = 0.01
|
|
Diuretic
|
2.31
|
0.24–22.47
|
p = 0.47
|
|
CCB
|
1.28
|
0.28–5.91
|
p = 0.75
|
|
ASA
|
2.28
|
0.42–12.49
|
p = 0.34
|
|
Statin
|
0.66
|
0.12–3.63
|
p = 0.63
|
